What you should know:
1. The guideline focuses on using oral and topical 5-aminosalicylates medications, rectal corticosteroids and oral budesonide to provide high-quality care.
2. The guideline is intended for patients with mild-to-moderate ulcerative colitis, but the treatments could have varying degrees of effectiveness among patients.
3. AGA does not address biologic therapies and/or immunomodulators with this guideline.
To view the entire guideline, click here.
More articles on gastroenterology:
The outlook is bright for orthopedic investments, analyst says: 4 things to know
Brooklyn Surgery Center partners with Fellow Health Partners for billing services — 3 insights
4 healthcare design trends to watch in 2019
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
